SectorChemical and pharmaceutical
Established Date12/06/2019
Listing Date12/03/2020
ExchangeNASDAQ Stock Exchange
Full-time Employees60
Fiscal Year Ends31/12
Security TypeCommon stock
Office address205 Park Road, Burlingame, California 94010
BusinessDevelops small molecule inhibitors for precision oncology.
IntroductionEnliven Therapeutics, Inc., was incorporated in Delaware on June 12, 2019. This clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule therapeutic drugs to help people not only live longer, but live better. The Company addresses existing and emerging unmet needs through a precision medicine approach that improves survival and enhances overall well-being. Its discovery process combines deep insights and differentiated chemistry on clinically proven biological targets with the goal of designing therapies that meet these unmet needs. By combining clinically validated targets and specific target product features with rigorous clinical trial design and regulatory strategies, we are committed to developing drugs that effectively meet unmet needs and increase the likelihood of clinical and commercial success. Currently, the company is advancing ELVN-001 and exploring multiple additional research stage opportunities consistent with its small molecule development strategy.